Procept Biorobotics Corp (PRCT)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 11:06 AM ET
Procept Biorobotics Corp (PRCT) Stock Forecast
Analysts expect Procept Biorobotics (PRCT) to earn -$1.72 per share in the fiscal year ending Dec 31, 2026, on revenue of $395.29M. Of 15 analysts, 5 rate the stock Buy or Strong Buy, 9 Hold and 1 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.23.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 33% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 3 | 20.0% |
| Hold | 9 | 60.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 6.7% |
- Consensus
- Hold
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 19.8%.
- Fiscal year ending Dec 31, 2026
- -$1.72
- EPS consensus, revenue $395.29M
- Fiscal year ending Dec 31, 2027
- -$1.23
- EPS consensus, revenue $473.67M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.72 | -$1.80 to -$1.63 | 13 | $395.29M | $389.00M to $401.51M | 14 |
| Dec 31, 2027 | -$1.23 | -$1.58 to -$0.86 | 13 | $473.67M | $458.33M to $483.04M | 14 |
Quarterly Estimates
The EPS consensus falls from -$0.25 for the quarter ending Dec 31, 2026 to -$0.43 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.25 | -$0.27 to -$0.20 | 17 | $120.40M | $102.76M to $131.88M | 16 |
| Mar 31, 2027 | -$0.43 | -$0.52 to -$0.34 | 11 | $104.60M | $101.40M to $108.20M | 10 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 8 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 6 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.68.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.72 | -$1.68 | -$1.68 | -$1.68 | -$1.68 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.23 | -$1.17 | -$1.15 | -$1.15 | -$1.15 | N/A |
| Quarter ending Mar 31, 2027 | -$0.43 | -$0.38 | -$0.38 | -$0.38 | -$0.38 | N/A |
Frequently Asked Questions About PRCT
What is the PRCT stock forecast?
Consensus analyst estimates put Procept Biorobotics's EPS at -$1.72 for the fiscal year ending Dec 31, 2026, on revenue of $395.29M. The consensus rating from 15 analysts is Hold.
How do analysts rate PRCT stock?
Of 15 analysts covering Procept Biorobotics, 2 rate it Strong Buy, 3 Buy, 9 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from PRCT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.72, with estimates from -$1.80 to -$1.63 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.23, with estimates from -$1.58 to -$0.86 from 13 analysts.
What revenue do analysts expect from Procept Biorobotics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $395.29M, with estimates from $389.00M to $401.51M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $473.67M, with estimates from $458.33M to $483.04M.
How many analysts cover PRCT?
15 analysts rate Procept Biorobotics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PRCT pages: Overview, Earnings, Forecast, Financials, Competitors